NASDAQ: PSNL Shares Soar 24.53% as Medicare Expands Breast Cancer Test Coverage

Personalis (NASDAQ: PSNL) shares surged 24.53% in pre-market trading on November 11, 2025, marking a significant pre-market gain driven by recent developments in its Medicare coverage and analyst sentiment.

The upward momentum followed a regulatory milestone as Medicare extended coverage for Personalis’ NeXT Personal MRD test for breast cancer. This approval, retroactive to October 7, 2025, provides reimbursement for monitoring cancer recurrence, positioning the company to expand into clinical diagnostics. Analysts at BTIG and H.C. Wainwright raised price targets to $12.00 and $13.00 respectively, citing the coverage as a “major derisking event” and underscoring the $20-30 billion potential in the MRD testing market.

Despite a 52% stock price increase over the past year, the company faces near-term challenges, including a 44% revenue decline in Q3 2025 compared to Q2. However, the recent Medicare expansion and partnerships, such as with Tempus, are expected to drive test volume growth starting in Q4 2025.

Backtesting strategies for PSNL could focus on volatility-driven patterns, given its beta of 2.01 and recent 28% intraday swings. A hypothetical approach might involve entering long positions after confirmed Medicare-related news events, with trailing stops to capitalize on momentum while mitigating downside risk.